The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/04 - Antineoplastic agents specific for metastasis
Triangle Environmental Health Initiative, LLC (USA)
Duke University (USA)
Inventor
Trotochaud, Lena
Miller, Graham H.
Hawkins, Brian T.
Forbis-Stokes, Aaron
Rogers, Tate
Dutoit, Marielle
Abstract
The present disclosure describes systems and methods for wastewater treatment. In some embodiments, a system may include one or more of a pair of electrodes, a first membrane selectively permeable to a first wastewater nutrient, a second membrane selectively permeable to a second wastewater nutrient, and at least one spacing frame comprising a structural element, a gasket, and a flow channel. In some embodiments, the system may further include a septic tank.
C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
Disclosed herein are binding molecules and/or antibodies targeting a universal influenza antigen and methods of using the same to treat a subject having an influenza infection and to minimize the progression of an influenza infection in a subject.
A method for treating cancer in an individual comprises administering to the individual a therapeutically effective amount of a PCSK9 inhibitor. The method may further comprise administering to the individual at least one immune checkpoint inhibitor.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present disclosure provides a gene delivery system in which transgenic mitochondria are administered to an animal to permit expression of the transgene and secretion of a transgene- encoded protein to an animal.
A DNA synthesis technology that relies on sequence-directed, multiplexed ligations to enable template-independent, exponential synthesis of gene- or genome-length DNA. This approach relies on well characterized and optimized enzymes and thus does not require further protein engineering. This approach is amenable to cost-effective automation and thus will enable cost-effective DNA “printers”.
Disclosed herein are compositions comprising nanoparticles designed for CRISPR/Cas13 RNA targeting systems, specifically aimed at targeting poorly druggable, disease-driving genes in prostate cancer and COVID-19, and methods of use thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and methods may increase the expression or protein level of a transcription factor selected from TGIF2LX, TGIF1, TGIF2, FOS, HNF4A, KLF8, NFKBIZ, CARF, EBF3, HMX3, LHX4, LMX1A, PLAG1, PLAGL1, POU2F3, SOX14, TFAP2D, and WT1, or a combination thereof. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
Cellulose-reinforced hydrogels may include a cellulose nanofiber network and an interstitial hydrogel portion within interstitial regions of the cellulose nanofiber network, the interstitial hydrogel portion comprising polyvinyl alcohol (PVA), wherein the hydrogel component has a crystallinity of 20% or greater.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
An on-spot abnormal tissue detection system includes a light source, a housing, a light fiber, a collimating lens, one or more beam combining mirrors, one or more focusing optic lenses, one or more achromatic doublet lenses, a spectrometer, a fiber optic cable, and a computing system. The computing system can receive wavelength intensity pairs for spot locations of the target area from the spectrometer, determine a standard deviation and variance measurement of the wavelength intensity pairs for the spot locations, determine whether tissue for the spot locations of the target area is a tissue type of a tumor or normal tissue based on the standard deviation and variance measurement of the wavelength intensity pairs, and send the determination of whether the tissue for the spot locations of the target area is a tissue type of a tumor or normal tissue to a display.
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
The application is drawn to radiolabeled biomolecules and methods for radiolabeling biomolecules with radioactive halogen atoms that minimizes loss of the radioactive halogen due to dehalogenation in vivo, preserves the biological activity of the biomolecule, maximizes retention of radioactivity in cancer cells, and minimizes the retention of radioactivity in normal tissues after in vivo administration. Some such radiolabeled biomolecules comprise a radioactive metal atom in place of, or in addition to the radioactive halogen. The biomolecules have an affinity for particular types of cells and may specifically bind a certain cell, such as cancer cells. Relevant biomolecules include antibodies, monoclonal antibodies, antibody fragments, peptides, other proteins, nanoparticles and aptamers.
09 - Scientific and electric apparatus and instruments
Goods & Services
Downloadable software for providing training and guidance to caregivers to support child development; Downloadable computer application software for mobile phones and handheld computers, namely, software for providing training and guidance to caregivers to support child development
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 35/04 - Antineoplastic agents specific for metastasis
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
15.
TEMPLATE DEVICES FOR PLACEMENT OF IMPLANT AND METHODS OF USE
The present disclosure provides devices, systems, and methods relating to performing a medical procedure. In particular, the present disclosure is directed to devices, systems, and methods for accurately positioning and securing a body implant in a subject. A template corresponds to the implant, and the template is configured to mark a desired location in a patient prior to positioning the implant at the desired location.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
The disclosure provides methods of treating cancer, such as an estrogen receptor negative (ER–) solid cancer or estrogen receptor-low (ERlow) solid cancer in a patient. The method may include administering to the patient an effective amount of lasofoxifene, or a pharmaceutically acceptable salt or functional derivative thereof.
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Disclosed herein are functionalized branched poly-lysine compounds and uses thereof, as well as delivery systems in which polymeric nanocarriers are functionalized with branched poly-lysine compounds. Also provided herein are uses of the functionalized branched poly-lysine compounds and the delivery systems for treating joint diseases such as osteoarthritis, and in delivering pharmaceutically active compounds to cartilage and subchondral bone.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
18.
PSMA targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy
Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.
The present disclosure describes, in part, biomarkers for the identification of aggressive prostate cancer by determining a castration-resistant prostate cancer (CRPC) evolutionary signature of prostate cells, and methods of use thereof.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and methods may increase the expression or protein level of a transcription factor selected from THAP6, DMRT3, MEF2B, PAX2, ATOH7, KLF2, KLF1, TWIST1, NKX6, and FEV, or a combination thereof. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.
The Governors of the University of Alberta (Canada)
Inventor
Kaddurah-Daouk, Rima
Wishart, David
Rayat, Dorsa Yahya
Abstract
The present disclosure describes, in part, devices, systems, and methods for connecting metabolomic measurements to big data being generated by sensors captured in databases to enable monitoring of metabolic health at molecular level to map disruptions in biochemical processes in each individual that can inform about basis of disease and ways to correct for such defects tailored for each individual.
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G16H 20/30 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
G16H 20/60 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to nutrition control, e.g. diets
G16H 20/90 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to alternative medicines, e.g. homeopathy or oriental medicines
22.
ANTIBODIES THAT TARGET HLA-E-HOST PEPTIDE COMPLEXES AND USES THEREOF
The Chancellor, Masters and Scholars of the University of Oxford (United Kingdom)
Inventor
Haynes, Barton F.
Saunders, Kevin O.
Li, Dapeng
Azoitei, Mihai
Walters, Lucy C.
Gillespie, Geraldine
Brackenridge, Simon
Mcmichael, Andrew James
Abstract
Recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E-peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK and/or CD8+ T-cells positive for cell-surface expression of NKG2A (“NKG2A+”). Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from HLA-E-VL9 peptide-immunized HLA-B transgenic mice and from the naive human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The invention provides methods for using HLA-E-VL9 m Abs to modulate NK and/or CD8+ T-cell function as part of immunotherapeutic strategies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Methods and system for music generation. One method comprises defining a phrase structure and a metrical layout, and generating a melody based on the phrase structure and the metrical layout using a probabilistic model of contour-sequences in a machine learning model. The probabilistic model includes a plurality of production rules determined by the machine learning model trained on a dataset of hierarchical analyses, and the contour-sequences defining directional patterns between musical notes extracted from the dataset of hierarchical analyses.
Disclosed herein are lipid nanoparticles including a POEGMA-lipid conjugate that can effectively encapsulate and deliver therapeutics without the immune consequences suffered by PEG-based counterparts. An example lipid nanoparticle includes an ionizable lipid, a phospholipid, a sterol, a POEGMA-lipid conjugate, and a therapeutic. Also disclosed herein are pharmaceutical compositions that include the POEGMA-based lipid nanoparticles, methods of treating a disease or disorder, and methods of delivering a therapeutic to a cell.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
25.
COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS
The present invention relates to compositions and methods for identifying odorant-odorant receptor interactions. In particular, the present invention relates to methods for identifying odorant receptor-odorant interactions based on odorant receptor amino acid sequence and other properties of odorant receptors and odorants. The methods provide, in part, for the broad surveying of OR responses, using an in vivo strategy, against a diverse panel of 10 odorants, followed by using the resulting interaction profiles to uncover relationships between OR responses, odorants, odor molecular properties, and OR sequences.
Genome sequencing identified a new gene associated with a cardiac arrhythmic disease, TAXI -binding protein 3. From cell line models and a conditional knock-out mouse models of the gene deletion, it was found that a specific molecule, transient receptor potential vanilloid 4 (TRPV4), is up-regulated and is associated with calcium mediated arrhythmic depolarizations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
28.
METHODS, COMPOSITIONS, AND KITS FOR TREATING AND/OR PREVENTING A SIDE EFFECT ASSOCIATED WITH RADIATION AND/OR CHEMOTHERAPY EXPOSURE
Described herein are methods, compositions, and kits for treating and/or preventing in a subject one or more side effects associated with radiation and/or chemotherapy exposure, including methods, compositions and kits that include an active agent at a low dose. In some embodiments, methods, compositions, and kits for treating and/or preventing tissue damage in a subject are provided, including methods, compositions and kits that include an active agent at a low dose.
The present disclosure provides methods of treating or preventing inflammatory bowel disease or sepsis in a subject by inhibiting SUMOylation in the subject.
The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and regulate the cytotoxicity effector cell function of NK. Herein, monoclonal antibodies were recombinantly derived from isolated functional HLA-E-VL9-specific mAbs from the naïve human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK cell function as part of immunotherapeutic strategies.
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
31.
COMPOSITIONS COMPRISING XBP1 FRAGMENTS AND METHODS OF USE IN GENE THERAPY
Disclosed herein are compositions comprising endoplasmic reticulum (ER) stress sensor variants. Disclosed herein are methods of using the disclosed compositions to maintain and/or establish ER homeostasis following transgene expression.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
32.
ALLOSTERIC MODULATORS OF THE BETA1-ADRENERGIC RECEPTOR AND METHODS OF USING SAME
Described herein are compositions and methods for treating, ameliorating, or inhibiting the progress of blood cancer in a cell or a subject. In some embodiments, the compositions and methods comprise one or more retinoid X receptor (RXR) modulators and one or more immunomodulatory agents. In some embodiments, the blood cancer is multiple myeloma (MM). In some embodiments, the subject has diabetes, dyslipidemia, or a combination thereof.
The present invention provides improved, methods to treat glioblastoma, including newly diagnosed glioblastoma (ndGBM) and recurrent glioblastoma (rGBM), in a human comprising administration to the patient of a chimeric poliovirus construct comprising a Sabin type I strain of poliovirus with a human rhinovirus 2 (HRV2) internal ribosome entry site (IRES) in the poliovirus 5' untranslated region between the poliovirus cloverleaf and the poliovirus open reading frame (a "chimeric poliovirus") by cervical perilymphatic subcutaneous injection, convection enhanced delivery (CED), direct intracavitary infusion via an Ommaya reservoir inserted into the surgical cavity, injection into the glioblastoma lesion cavity wall, or a combination thereof As provided herein, the chimeric poliovims is administered in a specifically-timed treatment regime comprising a treatment phases as a first-line treatment preceding the current standard of care glioblastoma therapy of maximum surgical resection, radiation, and temozolomide.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
36.
ELIMINATION CAPABILITY FOR ACTIVE MACHINE LEARNING
A method of datapoint elimination for an active learning algorithm includes monitoring datapoints in a labeled training dataset as new labeled datapoints are added to the labeled training dataset; determining whether datapoints in the labeled training dataset satisfy a criterion for elimination operations of an elimination protocol; and applying the elimination operations of the elimination protocol to remove one or more datapoints from the labeled training dataset.
A method for dynamically managing an energy system includes determining a production plan by determining a first stochastic system dynamic program (SSDP) based on a state of and a forecasted energy demand in the energy system, determining a second SSDP by relaxing the first SSDP, decomposing the second SSDP into energy unit-specific SSDPs, applying the unit-specific SSDPs with a price model to define a bound on the first SSDP, and determining a forward-looking dynamic economic dispatch plan based on the second SSDP by identifying actions for the energy units corresponding to reachable production levels, applying current unit-specific states and the identified actions to the production plan to generate an updated production plan including unit-specific actions and expected continuation values based on the second SSDP that modify subsequent actions, and dispatching the identified unit-specific actions to the energy system.
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (United Kingdom)
Inventor
Li, Dapeng
Mcmichael, Andrew James
Brackenridge, Simon
Gillespie, Geraldine
Azoitei, Mihai
Walters, Lucy C.
Saunders, Kevin O.
Haynes, Barton F.
Abstract
The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E-peptide complex, including HLA-E-VL9 complexes, and. regulate the cytotoxicity effector cell function of NK and/or CD8+ T-cells positive for cell-surface expression of NKG2A (“NKG2A+”). Herein, monoclonal antibodies were recombinant.lv derived from isolated functional HLA-E-VL9-specific mAbs from HLA-E-VL9 peptide-immunized HLA-B transgenic mice and from the naive human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity' and can preferentially recognize HLA-E-VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity 7 maturation. The invention provides methods for using affinity matured HLA-E-VL9 mAbs to modulate NK and/or CD8+T-cell function as part of immunotherapeutic strategies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
39.
METALLIC SINGLE-WALLED CARBON NANOTUBE HYBRID ASSEMBLIES AND SUPERSTRUCTURES
A metallic single-walled carbon nanotube (SWNT) hybrid assembly or superstructure includes a single walled carbon nanotube (SWNT) having a chiral index (n, m) where (n−m)/3 is an integer or 0; and an oligomer or polymer that single-chain wraps the metallic SWNT, wherein the oligomer or polymer is formed of repeat units, wherein each repeat unit has at least one charged functional group per 1-3 nm of oligomer or polymer length. The superstructure is suitable for optical, electro-optical, and spintronic-based device applications.
The present disclosure provides devices, systems, and methods relating to the treatment of glaucoma. In particular, the present disclosure is directed to hydrogel implants for use in glaucoma drainage devices to deliver therapeutic agents to a subject's eye and to obviate the need for tying off a drainage tube, thus enhancing therapeutic outcomes.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A readrRNA (RNA sensing by Endogenous ADAR) molecule is a modular RNA molecule that facilitates sensing and detection of a cell type or cell status of a cell, including a cell of a mammalian nervous system, such as a neuronal or non-neuronal cell of the mammalian central and/or peripheral nervous system, and/or facilitates delivery of an effector protein to the selected cell. A composition that includes such a modular RNA molecule and another nucleic acid (linked or unlinked to the modular RNA molecule) is a CellREADR (Cell access through RNA sensing by Endogenous ADAR). CellREADR senses the presence of a selected cell RNA in a cell of a mammalian nervous system via readrRNA and leverages RNA editing mediated by ADAR (adenosine deaminase acting on RNA) for coupling the detection of a cell-defining RNA with translation of one or more effector proteins in a cell of a mammalian nervous system.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
43.
MULTIFUNCTIONAL MICROELECTRONICS FIBERS AS IMPLANTABLE BIOELECTRONIC INTERFACES
Multifunctional microelectronics fiber probes can be chronically implanted in tissue of awake-behaving animals for understanding brain-viscera communication. These fiber probes can be made using thermal drawing to make hundreds of meters of flexible fiber that incorporates features such as light sources, electrodes, thermal sensors, and microfluidic channels in a multilayered configuration. The fiber mechanics can be tuned for two distinct device layouts: (1) higher-modulus, flexible brain fibers for implantation into deep-brain; and (2) soft, compliant gut fibers for implantation into the small intestine. Brain fibers can modulate the deep-brain mesolimbic reward pathway. Gut fibers can perform peripheral optogenetic stimulation of vagal afferents from the intestine to stimulate brain reward neurons. Brain and gut fibers can be connected to a control module, for example, with a coiled, stretchable interconnect that is more flexible and stretches more than even soft gut fibers, in dual-organ (gut-brain) implantation.
Knee implants having a convex outer surface formed of a stack of sheets of bacterial cellulose that is between 2-10 mm thick and has been impregnated and crosslinked to form a hydrogel having a concentration of cross-linked bacterial cellulose nanofibers of between 2-20 weight % of the hydrogel, so that the hydrogel has a tensile strength of greater than 5 MPa, a tensile modulus of greater than 8 MPa, and a compression strength of greater than 14 MPa. The implant may have a metallic body and may be generally mushroom-shaped.
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
C08L 33/26 - Homopolymers or copolymers of acrylamide or methacrylamide
C08L 41/00 - Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a bond to sulfur or by a heterocyclic ring containing sulfurCompositions of derivatives of such polymers
45.
SYSTEMS AND METHODS FOR PREDICTING VARIANT PATHOGENICITY BASED ON AMINO ACID SIGNAL-TO-NOISE RATIOS
Tools and related methods for analyzing the pathogenicity of gene variants are provided, the analysis being based on signal-to-noise ratios of the amino acids for the gene. The tools allow a user to input a gene, along with an amino acid position, and then the tool outputs information related to the susceptibility to a particular disease based on the inputted data as compared to information in a database about the gene, amino acid position, and/or other information. The information in the database can include data from others in the population and/or predicted information about the public, for example using artificial intelligence and other related predictive measures. The result is a tool, and related methodologies, that more accurately predict the true susceptibility for a patient to have or eventually get a particular disease than current tools, that tend to over-estimate the likelihood of having or getting such disease.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A gene therapy approach is described whereby augmentation of both peak sodium current and calcium transient amplitude in cardiomyocytes effectively alleviates pathologies of heart failure. Prokaryotic sodium channel gene delivery is described as a new therapy for reduced ejection fraction-associated heart failure.
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A system includes a reflective mask positioned in a first plane, a digital micromirror device (DMD) that is positioned in a second plane to receive transmitted light from the reflective mask via a non-confocal channel. The DMD includes micromirrors that rotate between an ON state and an OFF state. The system further includes an ON image detector that captures ON image data of the transmitted light directed by the micromirrors in the ON state and an OFF image detector that captures OFF image data of the transmitted light directed by the micromirrors in the OFF state. A method of image reconstruction includes using the captured data to compare against artificial image data created by a machine learning model/reconstruction network and iteratively updating weights (e.g., of the machine learning model/reconstruction network) for generating an artificial image from the artificial image data until a minimum threshold is reached.
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/14 - Arrangements specially adapted for eye photography
Disclosed herein are viral vectors for use in methods of developing HDAC-depleted cells. Disclosed herein are methods of increasing packaging capacity, increasing the titer, increasing the expression capacity, and decreasing the immunogenicity and/or toxicity of an optimized viral vector generated in HDAC-depleted cells.
The University of North Carolina at Chapel Hill (USA)
Inventor
Zhou, Pei
Toone, Eric J.
Nicholas, Robert A.
Gopalaswamy, Ramesh
Liang, Xiaofei
Navas, Iii, Frank
Abstract
Disclosed are compounds of formulae:
Disclosed are compounds of formulae:
Disclosed are compounds of formulae:
and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are usefμl for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.
C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 237/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 259/18 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxyamidine groups bound to carbon atoms of six-membered aromatic rings
C07C 311/06 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07C 317/18 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
C07C 317/44 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
C07D 203/08 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
C07D 203/18 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof
C07D 207/327 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 213/64 - One oxygen atom attached in position 2 or 6
C07D 263/16 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
C07D 277/40 - Unsubstituted amino or imino radicals
C07D 295/10 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms
C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
C07D 309/04 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. Combination with immune checkpoint inhibitors increases the anti-tumor effect. Tumors of different types are susceptible to the combination treatment, including but not limited to melanoma, glioglastoma, renal cell carcinoma, prostate cancer, breast cancer, lung cancer, medulloblastoma, and colorectal cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The present disclosure provides genetically modified flowering plants that produce seedless fruit and methods for making and cultivating such plants. The genetically modified flowering plants express a modified Auxin Response Factor 8A (ARF8A) or an ortholog thereof.
The disclosure provides compounds that inhibit the invasion of host cells by intracellular pathogens. The disclosure also relates to use of such compounds in methods of treating and preventing periodontitis or a periodontitis-related condition or symptom.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
Disclosed herein are polymer networks that include di- and tetra-functional cyclobutane mechanophores, where the mechanophores are incorporated into end-linked polymer networks. Methods of preparing such polymers and of using such polymers are also disclosed herein.
55.
COMPOSITIONS AND METHODS OF TREATING INVASIVE PATHOGENS
The disclosure provides compounds that inhibit the invasion of host cells by intracellular pathogens. The disclosure also relates to use of such compounds in methods of treating and preventing periodontitis or a periodontitis-related condition or symptom.
56.
COMPOSITIONS FOR AND METHODS OF EXPANDING γδ T CELLS
This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.
C07C 275/30 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
C07C 211/40 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
C07C 255/60 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
C07C 275/28 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
C07C 275/34 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
C07C 275/40 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 275/42 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
C07C 279/18 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
C07C 279/28 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
C07C 281/06 - Compounds containing any of the groups e.g. semicarbazides
C07C 317/36 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
C07D 213/75 - Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
C07D 223/04 - Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
C07D 229/02 - Heterocyclic compounds containing rings of less than five members having two nitrogen atoms as the only ring hetero atoms containing three-membered rings
C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
C07D 241/24 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
58.
COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING NEURODEGENERATIVE DISORDERS
Arizona Board of Regents on Behalf of the University of Arizona (USA)
Duke University (USA)
Inventor
Chang, Rui
Brinton, Roberta Diaz
Kaddurah-Daouk, Rima
Abstract
Provided herein are compositions and methods for diagnosing, prognosing, and treating neurodegenerative diseases in a male and female subject at risk of or diagnosed with a neurodegenerative disease. In particular, provided herein are customized metabolite analyses for characterizing and treating neurodegenerative diseases in specific subject groups from a sample from said subject.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
59.
Compositions For and Methods of Treating and/or Preventing Pain
Sanford Burnham Prebys Medical Discovery Inst. (USA)
Inventor
Barak, Lawrence
Caron (deceased), Marc
Slosky, Lauren
Ji, Ru-Rong
Pinkerton, Anthony
Abstract
Disclosed herein are compositions and pharmaceutical formulations comprising a functionally selected B-arrestin-biased NTSR1 ligand (such as SBI-553 and SBI-810) and methods of using those compositions and pharmaceutical formulations for treating and/or preventing pain.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A Fourier ptychography system includes a polarization-sensitive camera positioned for capturing a sequence of polarized images of a sample, an objective lens positioned in a light path between the polarization-sensitive camera and the sample, an array of light sources for directing light to the sample and a generator polarizer positioned between the array of light sources and the sample to polarize light directed to the sample from the array of light sources. A method of creating a tomographic Fourier ptychography image includes receiving, from a polarization-sensitive camera, a sequence of polarized images of a sample, stitching each image of the sequence of images together using a non-linear Fourier transform function to create a composite image, and outputting the composite image as the tomographic Fourier ptychography image. Each polarized image of the sequence of polarized images overlaps another polarized image of the sequence of polarized images.
H04N 23/951 - Computational photography systems, e.g. light-field imaging systems by using two or more images to influence resolution, frame rate or aspect ratio
Compositions are provided, the compositions comprising: (1) a nanoparticle; (2) optionally, a linker and/or masking agent, and (3) a ligand configured to activate peri-tumoral cells to induce scarring by the peri-tumoral cells. In some aspects, administration of the compositions to a subject may generate an environment capable of walling-off and containing invasive tumors.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
The present disclosure is directed to methods of treating a steatosis-associated disorder and methods of treating a cytoplasmic glycogen storage disorder, including glycogen storage disease I, glycogen storage disease III, glycogen storage disease IV, and/or conditions associated with a PRKAG2 mutation, by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage. Methods of treating a cytoplasmic glycogen storage disorder by administering a lysosomal enzyme and a second therapeutic agent are also described. Other embodiments are directed to methods of treating a cytoplasmic glycogen storage disorder by administering a therapeutic agent as an adjunctive therapy to lysosomal enzyme replacement therapy.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/7016 - Disaccharides, e.g. lactose, lactulose
A61K 33/00 - Medicinal preparations containing inorganic active ingredients
Reductions in costs to read and write DNA have driven advances in our ability to manipulate and engineer biology. However, writing DNA remains a limiting step in testing new hypotheses and engineering novel biological properties. Current synthesis methods lack the speed, low cost, and accessibility to match our current experimental outputs, such as high throughput screening and next generation sequencing. Ideally, DNA synthesis should become as ubiquitous and affordable as PCR. Such a step-change in affordability and accessibility would therefore lead to dramatic improvements in our ability to study and engineer biology. Towards this goal, we have developed a next generation DNA synthesis technology that relies on sequence-filtered, multiplexed ligations to enable template-independent, exponential synthesis of gene- or genome-length DNA. This approach is amenable to cost-effective automation and thus will enable cost-effective DNA "printers" that are as affordable as PCR machines.
Methods are provided for making caged gold nanostars (C-GNSs). In one method, a layer of gold is deposited on the silver layer of bimetallic nanostar (BNS) particles in a galvanic replacement-free reaction and the silver is subsequently removed via hydrogen peroxide etching. In another method, gold ions are exchanged with the silver atoms of the BNS particles in a galvanic replacement reaction. Both methods result in a hollow gold shell around a gold nanostar core that enables loading with dyes for in vitro and in vivo detection of the C-GNSs and provides an internal standard in sensing. The C-GNS particles have a greater local electric field enhancement from the visible to the NIR spectral range relative to plasmonic-active GNSs of similar diameter that lack the hollow gold shell. Dye-loaded C-GNS particles are demonstrated for in vivo hyperspectral imaging and as photothermal transducers in the treatment of solid tumors.
To overcome the limitations of existing methods for detecting short nucleic acid molecules of low abundance such as miRNA, the present inventors provide a non-enzymatic signal amplification method based on inverse molecular sentinel (iMS) nanoprobes to improve detection sensitivity. The method is based on a cascade toehold-mediated DNA strand displacement reaction triggered by a “linear” DNA strand called “Recycling Trigger Probe” (RTP) strand. In the method, iMS-OFF nanoprobes are incubated with targets and RTP strands. After turning on the first nanoprobe, the target undergoes a recycling process triggered by the RTP strands. This process allows the target to turn on more iMS nanoprobes and provide an amplified SERS signal.
Disclosed herein is a biochip with a plurality of endothelial cells (e.g., Schlemm's canal cells) having a plurality of pores (e.g., transcellular pores) and methods of making and using the same.
Disclosed herein are compositions and methods for treating cancer. The methods may include administering to a subject at least one estrogen receptor (ER) modulating drug. The methods may further include administering to the subject at least one additional therapy. Further provided herein are methods of predicting response of a subject to immune checkpoint blockade (ICB) therapy.
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
68.
METHODS AND SYSTEMS FOR PROCESSING A NUCLEIC ACID SAMPLE
The present disclosure provides methods and systems for processing a nucleic acid sample. The present disclosure also provides methods and systems for detecting (e.g., optically detecting) a pathogen in a sample. The methods provided herein may use nucleic acid amplification.
Disclosed herein are compositions, kits, and methods for identifying protein, miRNA, or metabolite biomarkers for dystonia, for treating a subject having a dystonia, for selecting a subject for a clinical trial, for selecting a therapeutic agent, for treatment of dystonia in a subject, for classifying a subject having dystonia, and for predicting responsiveness to a dystonia treatment.
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
41 - Education, entertainment, sporting and cultural services
Goods & Services
Providing information in the field of artificial intelligence; Providing information in the field of artificial intelligence via a website; Providing information in the field of artificial intelligence education for nursing and health professionals; Providing information in the field of artificial intelligence education for nursing and health professionals via a website; Educational services, namely, conducting seminars, webinars, workshops, classes, and conferences in the field of artificial intelligence; Educational services, namely, conducting seminars, webinars, workshops, classes, and conferences in the field of artificial intelligence for health care
42 - Scientific, technological and industrial services, research and design
Goods & Services
Providing temporary use of online non-downloadable computer chatbot software for simulating conversations; providing temporary use of online non-downloadable chatbot software for users to obtain information and data; providing temporary use of online nondownloadable chatbot software using artificial intelligence (AI) for users to obtain information and data; providing temporary use of online non-downloadable chatbot software for providing resources to users; providing temporary use of online non-downloadable chatbot software using artificial intelligence (AI) for providing resources to users; providing temporary use of online nondownloadable chatbot software for navigating online portals; providing temporary use of online nondownloadable chatbot software using artificial intelligence (AI) for navigating online portals; providing temporary use of online non-downloadable chatbot software for scheduling appointments and events; providing temporary use of online non-downloadable chatbot software using artificial intelligence (AI) for scheduling appointments and events; providing temporary use of online nondownloadable chatbot communication software for replying to questions from prospective and current users relating to medical services; providing temporary use of online nondownloadable artificial intelligence communication software for replying to questions from prospective and current users relating to medical services; providing temporary use of online non-downloadable chatbot software for patients to receive online results and feedback; providing temporary use of online non-downloadable chatbot software using artificial intelligence (AI) for patients to receive online results and feedback; providing temporary use of online non-downloadable chatbot software for patients to request information and records; providing temporary use of online non-downloadable chatbot software using artificial intelligence (AI) for patients to request information and records; providing temporary use of online non-downloadable chatbot software for making payments; providing temporary use of online non-downloadable chatbot software using artificial intelligence (AI) for making payments; providing temporary use of online nondownloadable chatbot software for replying to questions submitted by users; providing temporary use of online non-downloadable chatbot software using artificial intelligence (AI) for replying to questions submitted by users
72.
METHODS AND SYSTEMS FOR PROCESSING A NUCLEIC ACID SAMPLE
The present disclosure provides methods and systems for processing a nucleic acid sample. The present disclosure also provides methods and systems for detecting (e.g., optically detecting) a pathogen in a sample. The methods provided herein may use nucleic acid amplification.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
Described are oxysterols, pharmaceutical compositions including the oxysterols, and methods of using the oxysterols and compositions for treating diseases and/or disorders related to myelin injury, such as neonatal brain injury, traumatic brain injury, spinal cord injury, cerebral palsy, seizures, cognitive delay, multiple sclerosis, stroke, autism, leukodystrophy, schizophrenia and bipolar disorder.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
The present disclosure describes innovations to improve the use of stereo-EEG (sEEG) intreating epilepsy. The systems and methods include a fully automated platform for generating patient specific head models, a visualization of the tissue that can be recorded by a set of sEEG electrodes, an automated implantation trajectory planning algorithm that incorporates the tissue that can be recorded by a set of sEEG electrodes, and a dynamic source reconstruction algorithm that can visualize the epileptiform activity.
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
G06F 30/12 - Geometric CAD characterised by design entry means specially adapted for CAD, e.g. graphical user interfaces [GUI] specially adapted for CAD
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
75.
COMPOSITIONS FOR THE TREATMENT OF FOOD AND CHEMICAL ADDICTION AND METHODS OF MAKING AND USING SAME
Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating health conditions can include administering an effective amount of at least one of the compounds or compositions disclosed herein to a subject having or suspected of having an imbalance in brain dopamine homeostasis.
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
C07D 311/24 - Benzo [b] pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
76.
MNO NANOMATERIAL BASED INHIBITORS OF INFLAMMATION AND SARS-COV-2 VIRAL REPLICATION
The present invention provides methods for using an anionic manganese oxide (MnO) nanoparticle-based nucleic acid scavenger to (1) inhibit viral infection of cells, (2) reduce or inhibit a viral infection of a subject, and (3) reduce viral infection induced inflammation in a subject.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
77.
Compositions for the Treatment of Pathogenic- And/Or Chemical-Induced Lung Injury and for the Treatment of Cancer and Methods of Using Same
The present disclosure provides compositions and methods for the treatment of pathogen-induced and/or chemical-induced lung injury, for regenerating lung epithelial cells following lung injury, for treating cancer, and for sensitizing a subject suffering from cancer to a chemotherapeutic agent.
We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
Aspects of the present disclosure relate generally to systems and methods for use in the implementation and/or operation of quantum information processing (QIP) systems, and more particularly, to the use of qubit feedback for noise cancellation in quantum elements and/or quantum computations in QIP systems.
The present invention relates to methods of treating or preventing alcohol dependence, enhancing the treatment of alcohol dependence, treating alcohol withdrawal, reducing alcohol consumption, alleviating one or more alcohol withdrawal symptoms in a subject, preventing or reducing the likelihood of alcohol dependence relapse in a subject treated for alcohol dependence, preventing alcohol-related N-methyl-D-aspartate receptor (NMDA) upregulation, preventing alcohol-related NMDA receptor activity, comprising administering a therapeutically effective amount of an NMDA receptor partial agonist (e.g., rapastinel) to the subject. The present invention further relates to compositions comprising an NMDA receptor partial agonist (e.g., rapastinel) for use with the aforementioned methods.
Disclosed herein are compositions for use in methods of treating and/or preventing Glutaric Aciduria Type 1 and in methods of reprogramming a metabolic pathway.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A system and method comprises acquisition of a plurality of navigator k-space data segments and a k-space data segment associated with each of the plurality of navigator k-space data segments, generation of a respective navigator image from each of the plurality of navigator k-space data segments, determination, based on the respective navigator images of each of the plurality of navigator k-space data segments, of a first center navigator k-space data segment associated with a most common respiratory position of a subject, determination of a center k-space data segment corresponding to the first center navigator k-space data segment, determination, for each non-center segment of k-space, of a k-space data segment whose respective navigator image is most similar to a first center navigator image generated from the first center navigator k-space data segment, and generation of an image based on the determined k-space data segments.
Aspects of the present disclosure describe techniques that involve an active stabilization of coherent controllers using nearby qubits. In an aspect, a quantum information processing (QIP) system for stabilizing phase damping in qubits is described that provides a first and a second qubit ion, measuring magnetic field fluctuations using the second qubit ion, and generates one or more magnetic fields based on the measured magnetic field fluctuations, the one or more magnetic fields being applied near the first qubit ion to cancel the magnetic field fluctuations to stabilize the phase damping of the first qubit ion. Another such QIP system performs provides a first and a second qubit ion, locks a local oscillator to a frequency reference associated with the second qubit ion, and tracks, using the local oscillator, a frequency of the first qubit ion based on the frequency reference. Methods associated with these QIP systems are also described.
A thoracic device including a pair of sternal plates, each sternal plate of the pair of sternal plates including a body having a first end and a second end, a first arm extending from the first end of the body, the first arm having a cavity oriented transverse to the body and an aperture oriented parallel to the body, and a second arm extending from the second end of the body. The thoracic device includes a bar including a third end and a fourth end, the third end having a first channel and the fourth end having a second channel. The third end of the bar is received within the cavity of one of the pair of sternal plates and the fourth end of the bar is received within the cavity of the other one of the pair of sternal plates.
In various embodiments, the present invention is directed to an optically clear bottlebrush copolymers comprising one or more acryloxy or monomethacryloxy terminated polydimethylsiloxane (PDMS-MA) units, and or more acryloxy or monomethacryloxy terminated fluorinated siloxane (Fluoro-MA) units, and 2-cyano isobutane end groups. In addition to being optically clear, the viscosity and other properties of these bottlebrush copolymers are controllable making them suitable for a variety of applications. In some embodiments, the optically clear bottlebrush copolymers of the present invention will have complex viscosity (h) at 37 °C that make them are suitable for use as filler materials in intraocular lenses (IOLs) and accommodating or adaptive intraocular lenses (A-IOLs) for use in surgery for treating cataracts and other optical maladies.
C08F 230/08 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing silicon
87.
THERMALLY CONTROLLED INTEIN SPLICED DNA POLYMERASES AND METHODS OF MAKING AND USING THE SAME
The present invention relates to fusion proteins and methods of using the same. Specifically, invention relates to fusion proteins comprising an intein and a DNA polymerase having one or more substitution mutations relative to wildtype, and methods of using the same for DNA synthesis.
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
This invention is in the field of medicinal chemistry. In particular, the present disclosure provides methods for treating or preventing a fungal infection with one or more macrolide compounds, or pharmaceutically acceptable salts thereof, or compositions comprising the same and an additional anti-fungal agent, and pharmaceutical compositions comprising one or more macrolide compounds and at least one additional anti-fungal agent.
C07H 9/06 - Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (Israel)
DUKE UNIVERSITY (USA)
Inventor
Huleihel, Bashar
Aharoni, Ziv
Permuter, Haim Henry
Pfister, Henry
Abstract
A method comprising: using a neural successive cancellation (NSC) polar codes decoder for communication or decompression, wherein the NSC polar codes decoder comprises the following Artificial Neural Networks (ANNs): (a) when the NSC polar codes decoder is used for communication: an output statistics ANN; (b) when the NSC polar codes decoder is used for decompression: an input statistics ANN; (c) a check-node ANN; (d) a bit-node ANN; and (e) a soft decision operations ANN.
H03M 13/11 - Error detection or forward error correction by redundancy in data representation, i.e. code words containing more digits than the source words using block codes, i.e. a predetermined number of check bits joined to a predetermined number of information bits using multiple parity bits
90.
COMPOSITIONS AND SYSTEMS FOR RNA-PROGRAMMABLE CELL EDITING AND METHODS OF MAKING AND USING SAME
A readrRNA (RNA sensing by Endogenous ADAR) molecule is a modular RNA molecule that facilitates cell sensing and detection of a cell type or cell status and/or facilitates delivery of an effector protein to a selected cell. A composition that includes such a modular RNA molecule and another nucleic acid (linked or unlinked to the modular RNA molecule) is a CellREADR (Cell access through RNA sensing by Endogenous ADAR). readrRNA and CellReadR sense the presence of a selected cell RNA and leverages RNA editing mediated by ADAR (adenosine deaminase acting on RNA) for coupling the detection of a cell-defining RNA with translation of one or more effector proteins in a cell or in a mammal.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 9/00 - Medicinal preparations characterised by special physical form
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
C12N 15/67 - General methods for enhancing the expression
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
91.
NPR1 VARIANT TO ENHANCE PLANT RESISTANCE TO BIOTIC AND ABIOTIC STRESSES AND METHOD THEREOF
Described are NPR1 variants, nucleic acids encoding the NPR1 variants, and genetically modified plants expressing the NPR1 variants. Also described are methods of using nucleic acids encoding the NPR1 variants to genetically modify plants. The genetically modified plants exhibit increase resistance to biotic and abiotic stresses without compromising plant growth.
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
The disclosure provides compounds that inhibit the invasion of host cells by intracellular parasites. These find use, for example, in treating and preventing periodontitis or a periodontitis-related condition or symptom.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 8/02 - Cosmetics or similar toiletry preparations characterised by special physical form
A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/4748 - QuinolinesIsoquinolines forming part of bridged ring systems
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
The disclosure provides methods for treating estrogen receptor positive (ER+) cancer in women with an effective amount of lasofoxifene, a pharmaceutically acceptable salt thereof, or a prodrug thereof. The disclosure also includes the detection of the Estrogen Receptor 1 (ESR1) gene mutations that lead to endocrine resistance and treatment of endocrine resistant ER+ cancers.
A61K 31/00 - Medicinal preparations containing organic active ingredients
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 5/00 - Drugs for disorders of the endocrine system
A61P 35/04 - Antineoplastic agents specific for metastasis
C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
95.
GENE SIGNATURES FOR MONITORING ACUTE REJECTION AND METHODS OF USING SAME
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
96.
ADENO-ASSOCIATED VIRUS COMPOSITIONS AND METHODS OF USE THEREOF
Disclosed herein are adeno-associated virus (AAV) vectors comprising capsid protein variants. Also disclosed herein are pharmaceutical compositions comprising these AAV vectors and capsid protein variants as well as methods of making such vectors and capsid protein variants. Disclosed herein are methods of using the disclosed AAV vectors and disclosed capsid protein variants.
Disclosed herein are compositions and methods for inducing differentiation of an induced pluripotent stem cell (iPSC) or an embryonic stem cell (ESC) into a hepatocyte. The compositions and methods may also be used to promote maturation of a hepatocyte. The compositions and methods may include modulators of a gene selected from NHLH2, KLF7, GSC2, PPARG, SALL4, ESRRG, ESRRB, SMAD2, KLF6, TCF7, SMARCA2, SMAD3, TFEC, PURB, ZNF398, ASCL2, NFIB, ZIC4, ZNF618, FOXA2, NR5A1, FOXA3, HNF4A, HNF4G, HBP1, NHLH1, NR5A2, or YAF2, or a combination thereof, or a gene product thereof. The compositions and methods may be used for liver transplantations.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Technologies for providing pulse-level access in a quantum computing system based on a graph-based architecture include a compute device with circuitry configured to obtain pulse description data indicative of a graph representing one or more parameters of at least one waveform that defines at least one pulse. The circuitry may also be configured to perform analysis operations on the graph to determine properties of the at least one pulse and produce a corresponding target pulse description based on the analysis. The circuitry may be additionally configured to provide the target pulse description to a target application to produce the at least one pulse.
